Related Experiment Videos

Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment

Susan Kim1, Moussa El-Hallak1, Fatma Dedeoglu1

  • 1Children's Hospital Boston, Boston, Massachusetts.

Arthritis and Rheumatism
|May 30, 2009
PubMed

Insights

Aggressive treatment protocols for juvenile dermatomyositis (DM) can lead to sustained, medication-free remission in over half of patients. This approach achieved remission in a median of 38 months, improving outcomes and reducing complications.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Clinical Medicine

Background:

  • Juvenile dermatomyositis (DM) is a rare autoimmune disease affecting children, characterized by muscle inflammation and skin rash.
  • Effective treatment strategies are crucial to prevent long-term complications and achieve remission.

Purpose of the Study:

  • To evaluate the time to sustained, medication-free remission in juvenile DM patients treated with a stepwise, aggressive protocol.
  • To assess disease activity, calcinosis onset, growth effects, and medication-related complications.

Main Methods:

  • A cohort of 49 children with juvenile DM received standardized therapy with steroids and methotrexate, with additional medications added as needed.
  • Treatment followed a specific protocol at a tertiary care hospital between 1994 and 2004.
  • Primary outcome was time to complete remission; secondary outcomes included calcinosis, height, and complications.

Main Results:

  • A complete, medication-free remission was achieved in 28 out of 49 patients (57%), with a median time of 38 months.
  • No disease flares requiring medication resumption were observed in the remission group.
  • Mild treatment complications, primarily from steroids, were noted; no persistent effect on longitudinal growth was observed.

Conclusions:

  • Aggressive treatment of juvenile DM can lead to rapid control of inflammation and muscle weakness, improving patient outcomes.
  • Over half of the treated children achieved prolonged, medication-free remission, indicating the efficacy of this intensive approach.
  • This strategy may reduce disease-related complications and promote long-term recovery in juvenile DM.
Abstract

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...